These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38867863)

  • 21. Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.
    Ades M; Simard C; Vanassche T; Verhamme P; Eikelboom J; Mavrakanas TA
    Semin Nephrol; 2023 Nov; 43(6):151484. PubMed ID: 38272779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor XI, a potential target for anticoagulation therapy for venous thromboembolism.
    Li T; Liu J; Wu W
    Front Cardiovasc Med; 2022; 9():975767. PubMed ID: 36386334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
    Lewis SR; Pritchard MW; Schofield-Robinson OJ; Alderson P; Smith AF
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012584. PubMed ID: 30019463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders.
    Campello E; Simioni P; Prandoni P; Ferri N
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
    Smith EE; Shoamanesh A; Xu L; Heenan L; Saad F; Colorado P; Chen CH; Lemmens R; De Marchis GM; Caso V; Masjuan J; Hirano T; Milanov I; Campbell BCV; Mas JL; Connolly SJ; Mundl H; Hart RG;
    Stroke; 2024 Feb; 55(2):392-402. PubMed ID: 38174569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
    Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
    Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
    Vlădăreanu AM; Roşca A
    Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.
    Al Said S; Kaier K; Sumaya W; Alsaid D; Duerschmied D; Storey RF; Gibson CM; Westermann D; Alabed S
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD014678. PubMed ID: 38264795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new in anticoagulation: factor XI inhibitors.
    Muscente F; De Caterina R
    Eur Heart J Suppl; 2023 Apr; 25(Suppl B):B65-B68. PubMed ID: 37091652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.
    Bala MM; Paszek E; Lesniak W; Wloch-Kopec D; Jasinska K; Undas A
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012534. PubMed ID: 30004572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor XI: structure, function and therapeutic inhibition.
    Ali AE; Becker RC
    J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38622277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
    Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the contact system in patients with a first acute myocardial infarction.
    Konings J; Govers-Riemslag JW; Spronk HM; Waltenberger JL; ten Cate H
    Thromb Res; 2013 Jul; 132(1):138-42. PubMed ID: 23746628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological and clinical appraisal of factor XI inhibitor drugs.
    Occhipinti G; Laudani C; Spagnolo M; Finocchiaro S; Mazzone PM; Faro DC; Mauro MS; Rochira C; Agnello F; Giacoppo D; Ammirabile N; Landolina D; Imbesi A; Sangiorgio G; Greco A; Capodanno D
    Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):245-258. PubMed ID: 38196141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.